Merck Delayed Reporting Vioxx Mortality Risk in Alzheimer’s Patients – JAMA Article
This article was originally published in The Pink Sheet Daily
Executive Summary
Researchers say Merck did not provide a timely analysis of clinical trial data showing Vioxx increased risk of death in Alzheimer’s group.